Basic Information

Gene symbol TNFRSF17 Synonyms BCM, BCMA, CD269, TNFRSF13A Type of gene protein-coding
Description TNF receptor superfamily member 17

GTO ID GTC0446
Trial ID NCT03601078
Disease Multiple Myeloma
Altered gene BCMA
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment Abecma|bb2121|BMS-986395|Idecabtagene vicleucel|ide-cel
Location approved US, Canada, EU, UK, Japan, Israel, Switzerland
PhasePhase2
Recruitment statusRecruiting
TitleAn Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Year2018
CountryFrance|Germany|Italy|Spain|United Kingdom|United States
Company sponsorCelgene
Other ID(s)BB2121-MM-002|U1111-1216-4209|2018-000264-28
Vector information
Vectorlentivirus

Clinical Result

Cohort 1
Administration route None
Dosage 150~450E6 cells
Donor type Autologous
Pts 37
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 31/37(ORR); 14/37(CR); 4/37(SD); 0/37(PD)
Adverse reactions 100%(Grade 3-4 AEs); 35/37(neutropenia); 17/37(anemia); 14/37(thrombocytopenia); 1/37(Grade 3 cytokine release syndrome)
References DOI: 10.1182/blood-2022-162469

Relationship Graph

Overview of Knowledge Graph